Bristol Myers Squibb (BMY) Free Cash Flow Growth (1y) (2010 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (BMY) Free Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -11.32% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 125.17% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -13.16% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 107.90% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 96.00% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 1,829.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.16% |
| Mar 31, 2026 | -55.31% |
| Dec 31, 2025 | -60.50% |
| Sep 30, 2025 | 13.75% |
| Jun 30, 2025 | 72.29% |
| Mar 31, 2025 | -33.57% |
| Dec 31, 2024 | 3.54% |
| Sep 30, 2024 | 19.46% |
| Jun 30, 2024 | 26.78% |
| Mar 31, 2024 | -5.27% |
| Dec 31, 2023 | 32.50% |
| Sep 30, 2023 | 28.17% |
| Jun 30, 2023 | -18.15% |
| Mar 31, 2023 | -24.36% |
| Dec 31, 2022 | -20.79% |
| Sep 30, 2022 | -31.14% |
| Jun 30, 2022 | -30.21% |
| Mar 31, 2022 | -2.52% |
| Dec 31, 2021 | 21.65% |
| Sep 30, 2021 | 136.33% |